The efficacy of human epidermal growth factor receptor 2-targeted therapies, such as humanized monoclonal antibody trastuzumab (Herceptin®, Roche), in patients with breast-to-brain cancer metastasis is hindered by the low permeability of the blood-brain barrier (BBB).NeOnc conducted an in vitro and in vivo study to look at the ability of NEO100 to assist in delivering trastuzumab […]

A Phase 1 Human Trial of NEO100 was conducted to study the therapeutics’ survivability impact and tolerance capacity. NEO100, which is NeOnc Technology Holdings’ core formulation of highly purified Peryllil Alcohol (POH), has been shown to be a highly effective transport mechanism for delivering therapeutics to the brain for the treatment of diseases such as brain-based glioblastomas. […]